Clinical Trials
6
Active:1
Completed:0
Trial Phases
2 Phases
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (66.7%)Phase 2
2 (33.3%)Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
Phase 3
Not yet recruiting
- Conditions
- Platinum-Resistant Primary Peritoneal CarcinomaPlatinum Resistant High Grade Epithelial Ovarian CancerPlatinum Resistant High Grade Serous Ovarian Cancer
- Interventions
- Drug: Paclitaxel Lipid SuspensionDrug: Conventional paclitaxel or Taxol
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 166
- Registration Number
- NCT06867562
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer, MCRPC
- Interventions
- Drug: 50 mg cabazitaxelDrug: 100 mg cabazitaxelDrug: 200 mg cabazitaxel
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06890832
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
Phase 2
Not yet recruiting
- Conditions
- Ulcerative Colitis (UC)Ulcerative Colitis, Active Moderate
- Interventions
- Drug: Tacrolimus Lipid Suspension for enemaDrug: Identical Tacrolimus-free Lipid Suspension for Enema
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06867042
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Phase 3
Active, not recruiting
- Conditions
- Bipolar 1 Disorder
- Interventions
- Drug: Endoxifen enteric-coated tablet (8 mg)Drug: Placebo Tablets
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 490
- Registration Number
- NCT06608641
- Locations
- 🇺🇸
Synexus, Cerritos, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
🇺🇸Innovative Clinical Research, Inc., Miami Lakes, Florida, United States
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jina Pharmaceuticals Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04315792
- Locations
- 🇺🇸
16420 NW 59 Avenue, Miami, Florida, United States
- Prev
- 1
- 2
- Next
News
No news found